Caitlin Raymond: Understanding IgA Deficiency and Anaphylaxis Risk
Caitlin Raymond, a board-certified Clinical Pathologist and current Transfusion Medicine Fellow at the National Institutes of Health, shared a post on LinkedIn:
“Somewhere in a chart, someone typed IgA deficient.
No level.
No reaction history.
Just the label.
And because the label exists, every transfusion from here on is ordered as washed red cells and IgA-deficient plasma.
But do we actually know what were protecting against?
- Immunology defines selective IgA deficiency as under 7 mg/dL. Transfusion medicine uses under 0.05 mg/dL, confirmed by a send-out assay. Those are very different populations.
- Roughly 20 to 40% of IgA-deficient patients develop anti-IgA, yet donor studies show no increase in reactions in recipients of anti-IgA-containing components.
- Anti-IgA is estimated to account for only a small fraction of anaphylactic transfusion reactions.
- Canadian Blood Services recommends testing after a documented severe reaction, not as a prophylactic screen.
Our ordering habits are more conservative than the guidance.
I don’t think the evidence was ignored.
I think it never quite dispersed a caution built into practice decades ago, and nobody circled back to ask whether that caution still fits.
Next time IgA deficient shows up with no further detail, is did we wash the cells the right question?
What does your blood bank do when the label is all you have?”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series